<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22583576</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1748-6963</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nanomedicine (London, England)</Title>
                <ISOAbbreviation>Nanomedicine (Lond)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1311-37</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The present study reports a novel approach for enhancing the oral absorption and hypoglycemic activity of insulin via encapsulation in folate-(FA) coupled polyethylene glycol (PEG)ylated polylactide-co-glycolide (PLGA) nanoparticles (NPs; FA-PEG-PLGA NPs).</AbstractText>
                <AbstractText Label="MATERIALS &amp; METHODS" NlmCategory="METHODS">Insulin-loaded FA-PEG-PLGA NPs (size ∼260 nm; insulin loading ∼6.5% [w/w]; encapsulation efficiency: 87.0 ± 1.92%) were prepared by double-emulsion solvent evaporation method. The bioavailability and hypoglycemic activity of orally administered FA-insulin NPs were studied in diabetic rats.</AbstractText>
                <AbstractText Label="RESULTS &amp; CONCLUSION" NlmCategory="CONCLUSIONS">FA-PEG-PLGA NPs (50 U/kg) exhibited a twofold increase in the oral bioavailability (double hypoglycemia) without any hypoglycemic shock as compared to subcutaneously administered standard insulin solution. Insulin NPs maintained a continual blood glucose level for 24 h, which, however, was transient (&lt;8 h) in the case of subcutaneous insulin and associated with severe hypoglycemic shock. Overall, we have developed a patient-compliant, oral nanoformulation of insulin, once-daily administration of which would be sufficient to control diabetes for at least 24 h.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Sanyog</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education &amp; Research, Sector 67, SAS Nagar, (Mohali), Punjab 160062, India. sanyogjain@niper.ac.in</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rathi</LastName>
                    <ForeName>Vishal V</ForeName>
                    <Initials>VV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Amit K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Das</LastName>
                    <ForeName>Manasmita</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Godugu</LastName>
                    <ForeName>Chandraiah</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>05</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nanomedicine (Lond)</MedlineTA>
            <NlmUniqueID>101278111</NlmUniqueID>
            <ISSNLinking>1743-5889</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1SIA8062RS</RegistryNumber>
                <NameOfSubstance UI="D000077182">Polylactic Acid-Polyglycolic Acid Copolymer</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>26009-03-0</RegistryNumber>
                <NameOfSubstance UI="D011100">Polyglycolic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33X04XA5AT</RegistryNumber>
                <NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>935E97BOY8</RegistryNumber>
                <NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011100" MajorTopicYN="N">Polyglycolic Acid</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077182" MajorTopicYN="N">Polylactic Acid-Polyglycolic Acid Copolymer</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22583576</ArticleId>
            <ArticleId IdType="doi">10.2217/nnm.12.31</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
